SEARCH

SEARCH BY CITATION

References

  • 1
    Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA. 2005; 294: 238-244.
  • 2
    Chuba PJ, Moughan J, Forman JD, Owen J, Hanks G. The 1989 patterns of care study for prostate cancer: 5-year outcomes. Int J Radiat Oncol Biol Phys. 2001; 50: 325-334.
  • 3
    Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008; 58: 71-96.
  • 4
    Roach M3rd, Lu J, Pilepich MV, et al. Predicting long-term survival, and the need for hormone therapy: a meta-analysis of RTOG prostate cancer trials. Int J Radiat Oncol Biol Phys. 2000; 47: 617-627.
  • 5
    Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet. 2002; 360: 103-106.
  • 6
    D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA. 2004; 292: 821-827.
  • 7
    Denham JW, Steigler A, Lamb DS, et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol. 2005; 6: 841-850.
  • 8
    Laverdiere J, Nabid A, De Bedoya LD, et al. The efficacy and sequencing of a short course of androgen suppression on freedom from biochemical failure when administered with radiation therapy for T2-T3 prostate cancer. J Urol. 2004; 171: 1137-1140.
  • 9
    Pilepich MV, Winter K, John MJ, et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2001; 50: 1243-1252.
  • 10
    Pilepich MV, Winter K, Lawton CA, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma—long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys. 2005; 61: 1285-1290.
  • 11
    Roach M3rd, Bae K, Speight J, et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol. 2008; 26: 585-591.
  • 12
    See WA, Tyrrell CJ. The addition of bicalutamide 150 mg to radiotherapy significantly improves overall survival in men with locally advanced prostate cancer. J Cancer Res Clin Oncol. 2006; 132( suppl 1): S7-S16.
  • 13
    D'Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA. 2008; 299: 289-295.
  • 14
    Bolla M, Collette L, Van Tienhoven, G, et al. Ten-year results of long-term adjuvant androgen deprivation with goserelin in patients with locally advanced prostate cancer treated with radiotherapy: a phase III EORTC Study. Int J Radiat Oncol Biol Phys. 2008; 72: S30-S31.
  • 15
    Denham JW, Steigler A, Wilcox C, et al. Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: evidence from the TROG 96.01 randomised controlled trial. Lancet Oncol. 2008; 9: 1058-1068.
  • 16
    Pignon JP, Hill C. Meta-analyses of randomised clinical trials in oncology. Lancet Oncol. 2001; 2: 475-482.
  • 17
    Bria E, Nistico C, Cuppone F, et al. Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients. Cancer. 2006; 106: 2337-2344.
  • 18
    Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Intervention 4.2.6. The Cochrane Library, Issue 4. Chichester, UK: John Wiley & Sons, Ltd.; 2006.
  • 19
    Case LD, Kimmick G, Paskett ED, Lohman K, Tucker R. Interpreting measures of treatment effect in cancer clinical trials. Oncologist. 2002; 7: 181-187.
  • 20
    Bria E, Gralla RJ, Raftopoulos H, et al. Magnitude of benefit of adjuvant chemotherapy for non-small cell lung cancer: meta-analysis of randomized clinical trials. Lung Cancer. 2009; 63: 50-57.
  • 21
    Parmar MKB, Machin D. Survival Analysis: A Practical Approach. Chichester, UK: John Wiley & Sons, Ltd.; 1995.
  • 22
    Altman DG. Confidence intervals for the number needed to treat. BMJ. 1998; 317: 1309-1312.
  • 23
    Bolla M, van Tienhoven G, de Reijke TM, et al. Concomitant and adjuvant androgen deprivation (ADT) with external beam irradiation (RT) for locally advanced prostate cancer: 6 months versus 3 years ADT—Results of the randomized EORTC phase III trial 22961 [abstract]. J Clin Oncol. 2007; 25( 18 suppl): 5014.
  • 24
    Crook J, Ludgate C, Malone S, et al. Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2004; 60: 15-23.
  • 25
    Horwitz EM, Bae K, Hanks GE, et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol. 2008; 26: 2497-2504.
  • 26
    Djulbegovic B, Soares HP, Kumar A. What kind of evidence do patients and practitioners need: evidence profiles based on 5 key evidence-based principles to summarize data on benefits and harms. Cancer Treat Rev. 2006; 32: 572-576.
  • 27
    Soares HP, Kumar A, Djulbegovic B. Evidence profiles for breast cancer: benefit/harms data based on the totality of randomized evidence. Cancer Treat Rev. 2007; 33: 87-89.
  • 28
    De Laurentiis M, Cancello G, D'Agostino D, et al. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol. 2008; 26: 44-53.
  • 29
    Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008; 26: 3552-3559.
  • 30
    Feigenberg SJ, Hanlon AL, Horwitz EM, Uzzo RG, Eisenberg D, Pollack A. Long-term androgen deprivation increases grade 2 and higher late morbidity in prostate cancer patients treated with 3-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys. 2005; 62: 397-405.
  • 31
    Martinez AA, Demanes DJ, Galalae R, et al. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime. Int J Radiat Oncol Biol Phys. 2005; 62: 1322-1331.
  • 32
    Dearnaley DP, Sydes MR, Graham JD, et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol. 2007; 8: 475-487.
  • 33
    D'Amico AV, Denham JW, Crook J, et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol. 2007; 25: 2420-2425.
  • 34
    Efstathiou JA, Bae K, Shipley WU, et al. Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. J Clin Oncol. 2009; 27: 92-99.
  • 35
    Smith MR, Bae K, Efstathiou JA, et al. Diabetes and mortality in men with locally advanced prostate cancer: RTOG 92-02. J Clin Oncol. 2008; 26: 4333-4339.
  • 36
    Tsai HK, D'Amico AV, Sadetsky N, Chen MH, Carroll PR. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst. 2007; 99: 1516-1524.
  • 37
    Shelley MD, Kumar S, Wilt T, Staffurth J, Coles B, Mason MD. A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma. Cancer Treat Rev. 2009; 35: 9-17.
  • 38
    Piedbois P, Buyse M. Meta-analyses based on abstracted data: a step in the right direction, but only a first step. J Clin Oncol. 2004; 22: 3839-3841.
  • 39
    Bria E, Gralla RJ, Raftopoulos H, Giannarelli D. Comparing 2 methods of meta-analysis in clinical research—individual patient data-based (IPD) and literature-based abstracted data (AD) methods: analyzing 5 oncology issues involving more than 10,000 patients in randomized clinical trials (RCTs) [abstract]. J Clin Oncol. 2007; 25( 18 suppl): 6512.